Developer docs
API playgroundTry for free, no card

Search company profiles

バイオジェン・ジャパン(株)

Full company profile

uuid003zl6b

Namestring
バイオジェン・ジャパン(株)
Legal namestring
バイオジェン・ジャパン株式会社
Websiteurl
biogen.co.jp
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Biogen Japan Ltd. (バイオジェン・ジャパン株式会社) is a Tokyo-headquartered, wholly-owned subsidiary of Biogen Inc. (NASDAQ: BIIB), a global neuroscience-focused biopharmaceutical company. The Japanese entity focuses on the development, registration, and commercialization of therapies for serious neurological and neurodegenerative diseases, with named franchises covering Alzheimer's disease (co-promoted with Eisai), amyotrophic lateral sclerosis (ALS), multiple sclerosis (co-promoted with Sanofi), and spinal muscular atrophy (co-promoted with Nippon Shinyaku / Japan Pharma). The company maintains a registered office in Nihonbashi, Chuo-ku, Tokyo, and is led by Representative Director and President 傳 幸晴 (Yukiharu Den). Its mission statement publicly emphasizes "patient-centered decisions" (患者さんが中心の決断), and its commercial activities are anchored in a co-promotion model that leverages the domestic sales infrastructure of established Japanese pharmaceutical partners rather than a fully independent salesforce.

The company's business model is a classic specialty-pharma distribution model: it licenses or originates therapies from the Biogen Inc. global pipeline, secures PMDA approval in Japan, and then distributes to hospitals, clinics, and specialty pharmacies through partner-led or hybrid sales channels. Revenue is generated through drug sales reimbursed under Japan's national health insurance system, with pricing subject to biennial NHI price revisions. Patient-facing engagement is delivered through disease-awareness campaigns (notably a nationwide TVCM for Mild Cognitive Impairment scheduled to begin May 1, 2026), patient-advocacy storytelling (e.g., Daiichi-san and Fuu-chan), and multi-channel social media presence on Facebook, Twitter, YouTube, and Instagram. The subsidiary has also extended beyond pure drug commercialization into a dedicated Digital Health division (バイオジェン・デジタルヘルス), signaling an intent to layer digital services, patient support tools, and potentially digital therapeutics on top of its pharmaceutical core. No standalone revenue, headcount, or R&D spend is publicly disclosed, as all material figures are consolidated into Biogen Inc.'s group reporting.

Short descriptiontext

Biogen Japan is a Tokyo-headquartered, wholly-owned subsidiary of Biogen Inc. that develops and commercializes therapies for Alzheimer's, ALS, multiple sclerosis, and spinal muscular atrophy in the Japanese market, using co-promotion partnerships with Eisai, Sanofi, and Nippon Shinyaku for distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurology therapeutics, biopharmaceutical products, rare disease treatments, digital health solutions, neuroscience biotechnology
Industry4 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals - Neurology and Rare Disease Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Pharmaceutical Products
TypeSubscription Recurring
Description

Biogen Japan commercializes globally developed biopharmaceutical therapies for neurology, neuropsychiatry, specific immunology, and rare disease indications within Japan, generating revenue through product sales to hospitals, clinics, and pharmacies.

biogen.co.jp
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biogen Japan develops, registers, and commercializes prescription biopharmaceutical therapies for serious neurological and rare diseases in the Japanese market, with therapeutic focus on Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and spinal muscular atrophy (SMA). The company also operates a Biogen Digital Health division dedicated to individualized digital healthcare solutions in neuroscience. Revenue is generated through product sales to hospitals, clinics, and pharmacies via authorized wholesalers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Biogen is a science-led global biotechnology company that pushes the boundaries of science to develop innovative treatments for complex and serious diseases. The company operates across four key therapeutic areas: Alzheimer's disease, ALS (amyotrophic lateral sclerosis), Multiple Sclerosis, and Spinal Muscular Atrophy. Additionally, Biogen Japan has a dedicated Digital Health division (バイオジェン・デジタルヘルス) focused on individualized digital healthcare solutions in neuroscience. The company also maintains collaborative relationships with other pharmaceutical companies including Sanofi, Eisai, and Nippon Shinyaku for purposes such as joint seminars, disease awareness, and safety information management.

Product and service5 records
1Alzheimer's Disease Treatment (アルツハイマー病治療)
CategoryNeurology Therapeutics
Description

Prescription biopharmaceutical therapy for Alzheimer's disease, a neurodegenerative condition affecting memory and cognitive function, offered to neurologists and specialized memory clinics in Japan.

2ALS (Amyotrophic Lateral Sclerosis) Treatment (筋萎縮性側索硬化症治療)
CategoryNeurology Therapeutics
Description

Prescription therapy for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease affecting motor nerve cells, targeted at neurologists and ALS-specialized centers in Japan.

3Multiple Sclerosis (MS) Treatment (多発性硬化症治療)
CategoryNeurology Therapeutics
Description

Prescription therapy for multiple sclerosis (MS), a chronic condition affecting the central nervous system, offered to neurologists and MS-specialized hospitals in Japan.

4Spinal Muscular Atrophy (SMA) Treatment (脊髄性筋萎縮症治療)
CategoryRare Disease Therapeutics
Description

Prescription therapy for spinal muscular atrophy (SMA), a genetic disorder causing muscle weakness and atrophy, offered to neurologists and pediatric neuromuscular specialists in Japan.

5Biogen Digital Health (バイオジェン・デジタルヘルス)
CategoryDigital Health Solutions
Description

A digital health initiative within Biogen Japan focused on achieving individualized digital healthcare in neuroscience, aimed at transforming patient lives and Biogen's business through digital tools and solutions.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeGTM or Marketing Partner
Description

Sanofi and Biogen Japan jointly utilize healthcare professional personal data for co-hosted seminars, speaker invitations, and disease awareness campaigns targeting healthcare professionals in Japan. Data management responsibility lies with Biogen Japan.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Japan Pharma collaborates with Biogen Japan on co-promotion activities and healthcare professional engagement related to disease awareness and product information in Japan.

3Eisai (エーザイ株式会社)
Strategic tierCoreTypeGTM or Marketing Partner
Description

Eisai and Biogen Japan share healthcare professional data for disease awareness, medical product information provision, treatment support, adverse event safety information management, and post-marketing surveillance in Japan.

biogen.co.jp
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Major Japanese pharma with a CNS/psychiatry franchise (e.g., aripiprazole and related products). Comparable to Biogen Japan in targeting the same neurology/psychiatry specialist channel and in using co-promotion-style commercial models in Japan.

2Eisai Co., Ltd.
TypeDirect peer
Description

Japanese global pharma with a leading neuroscience franchise, most notably lecanemab (Leqembi) for Alzheimer's disease. Direct competitor to Biogen Japan in CNS and Alzheimer's, while simultaneously a co-promotion partner, making it the most directly comparable peer.

TypeBroad incumbent
Description

Japan's largest pharma with broad neuroscience, rare disease, and plasma-derived therapy franchises. A larger, broadly diversified incumbent with overlapping neurology/rare-disease capability but a much wider portfolio than Biogen Japan.

TypeBroad incumbent
Description

Major Japanese pharma with broad therapeutic areas including neurology adjacencies. While not as CNS-focused as Biogen Japan, it competes for the same specialty-pharma talent, HCP relationships, and co-promotion partners in Japan.

TypeDirect peer
Description

Global biopharma with multiple sclerosis and rare disease franchises (e.g., teriflunomide/Aubagio). Both a co-promotion partner to Biogen Japan and a direct competitor in MS and rare neurological indications in Japan.

TypeDirect peer
Description

Operates in Japan's neurology/MS space (e.g., MS therapies) and is a major multinational biopharma with neuroscience exposure. Comparable to Biogen Japan in product category (specialty neurology biologics) and in serving similar specialist HCPs in Japan.

7Sumitomo Pharma Co., Ltd.
TypeDirect peer
Description

Japanese specialty pharma with a strong CNS/psychiatry pipeline (e.g., latuda, regenerative medicine programs). Competes with Biogen Japan in the same specialist neurology and psychiatry prescriber base in Japan.

TypeEmerging player
Description

Specialty neurology biopharma with strong presence in epilepsy and rare disease in Japan (e.g., Vimpat, Briviact). Comparable as a specialty/CNS-focused player with concentrated therapeutic-area depth in Japan rather than broad pharma scale.

9Chugai Pharmaceutical Co., Ltd.
TypeBroad incumbent
Description

A Roche-group Japanese biopharma with strong specialty/biologics capabilities (e.g., NMOSD therapy). Comparable in being a Japan-resident biopharma with biologics-heavy product mix and similar regulatory/commercial dynamics.

TypeEmerging player
Description

Japanese specialty biopharma focused on rare diseases and specialty immunology/neurology (e.g., HLH, rare metabolic). A smaller, focused Japanese peer with rare-disease specialty model comparable to Biogen Japan's SMA franchise approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

バイオジェン・ジャパン(株)

Biopharmaceuticals - Neurology and Rare Disease Therapeuticsbiogen.co.jp

Biogen Japan is a Tokyo-headquartered, wholly-owned subsidiary of Biogen Inc. that develops and commercializes therapies for Alzheimer's, ALS, multiple sclerosis, and spinal muscular atrophy in the Japanese market, using co-promotion partnerships with Eisai, Sanofi, and Nippon Shinyaku for distribution.

What バイオジェン・ジャパン(株) does

Biogen Japan Ltd. (バイオジェン・ジャパン株式会社) is a Tokyo-headquartered, wholly-owned subsidiary of Biogen Inc. (NASDAQ: BIIB), a global neuroscience-focused biopharmaceutical company. The Japanese entity focuses on the development, registration, and commercialization of therapies for serious neurological and neurodegenerative diseases, with named franchises covering Alzheimer's disease (co-promoted with Eisai), amyotrophic lateral sclerosis (ALS), multiple sclerosis (co-promoted with Sanofi), and spinal muscular atrophy (co-promoted with Nippon Shinyaku / Japan Pharma). The company maintains a registered office in Nihonbashi, Chuo-ku, Tokyo, and is led by Representative Director and President 傳 幸晴 (Yukiharu Den). Its mission statement publicly emphasizes "patient-centered decisions" (患者さんが中心の決断), and its commercial activities are anchored in a co-promotion model that leverages the domestic sales infrastructure of established Japanese pharmaceutical partners rather than a fully independent salesforce.

The company's business model is a classic specialty-pharma distribution model: it licenses or originates therapies from the Biogen Inc. global pipeline, secures PMDA approval in Japan, and then distributes to hospitals, clinics, and specialty pharmacies through partner-led or hybrid sales channels. Revenue is generated through drug sales reimbursed under Japan's national health insurance system, with pricing subject to biennial NHI price revisions. Patient-facing engagement is delivered through disease-awareness campaigns (notably a nationwide TVCM for Mild Cognitive Impairment scheduled to begin May 1, 2026), patient-advocacy storytelling (e.g., Daiichi-san and Fuu-chan), and multi-channel social media presence on Facebook, Twitter, YouTube, and Instagram. The subsidiary has also extended beyond pure drug commercialization into a dedicated Digital Health division (バイオジェン・デジタルヘルス), signaling an intent to layer digital services, patient support tools, and potentially digital therapeutics on top of its pharmaceutical core. No standalone revenue, headcount, or R&D spend is publicly disclosed, as all material figures are consolidated into Biogen Inc.'s group reporting.

バイオジェン・ジャパン(株) firmographics

Firmographics
Name
バイオジェン・ジャパン(株)
Legal name
バイオジェン・ジャパン株式会社
Website
https://biogen.co.jp
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Biogen Japan is a Tokyo-headquartered, wholly-owned subsidiary of Biogen Inc. that develops and commercializes therapies for Alzheimer's, ALS, multiple sclerosis, and spinal muscular atrophy in the Japanese market, using co-promotion partnerships with Eisai, Sanofi, and Nippon Shinyaku for distribution.
Ownership category
akta.pro rank

バイオジェン・ジャパン(株) industry classification

Industry
Product category
Biopharmaceuticals - Neurology and Rare Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Neurology therapeutics
  • Biopharmaceutical products
  • Rare disease treatments
  • Digital health solutions
  • Neuroscience biotechnology

Where バイオジェン・ジャパン(株) is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

バイオジェン・ジャパン(株) business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Prescription Pharmaceutical Products: Biogen Japan commercializes globally developed biopharmaceutical therapies for neurology, neuropsychiatry, specific immunology, and rare disease indications within Japan, generating revenue through product sales to hospitals, clinics, and pharmacies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

バイオジェン・ジャパン(株) product offering

Product offering

Core offering

Biogen Japan develops, registers, and commercializes prescription biopharmaceutical therapies for serious neurological and rare diseases in the Japanese market, with therapeutic focus on Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and spinal muscular atrophy (SMA). The company also operates a Biogen Digital Health division dedicated to individualized digital healthcare solutions in neuroscience. Revenue is generated through product sales to hospitals, clinics, and pharmacies via authorized wholesalers.

Product overview

Biogen is a science-led global biotechnology company that pushes the boundaries of science to develop innovative treatments for complex and serious diseases. The company operates across four key therapeutic areas: Alzheimer's disease, ALS (amyotrophic lateral sclerosis), Multiple Sclerosis, and Spinal Muscular Atrophy. Additionally, Biogen Japan has a dedicated Digital Health division (バイオジェン・デジタルヘルス) focused on individualized digital healthcare solutions in neuroscience. The company also maintains collaborative relationships with other pharmaceutical companies including Sanofi, Eisai, and Nippon Shinyaku for purposes such as joint seminars, disease awareness, and safety information management.

Differentiator

Problem solved

Functional benefit

Products and services

  • Alzheimer's Disease Treatment (アルツハイマー病治療) Prescription biopharmaceutical therapy for Alzheimer's disease, a neurodegenerative condition affecting memory and cognitive function, offered to neurologists and specialized memory clinics in Japan.
  • ALS (Amyotrophic Lateral Sclerosis) Treatment (筋萎縮性側索硬化症治療) Prescription therapy for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease affecting motor nerve cells, targeted at neurologists and ALS-specialized centers in Japan.
  • Multiple Sclerosis (MS) Treatment (多発性硬化症治療) Prescription therapy for multiple sclerosis (MS), a chronic condition affecting the central nervous system, offered to neurologists and MS-specialized hospitals in Japan.
  • Spinal Muscular Atrophy (SMA) Treatment (脊髄性筋萎縮症治療) Prescription therapy for spinal muscular atrophy (SMA), a genetic disorder causing muscle weakness and atrophy, offered to neurologists and pediatric neuromuscular specialists in Japan.
  • Biogen Digital Health (バイオジェン・デジタルヘルス) A digital health initiative within Biogen Japan focused on achieving individualized digital healthcare in neuroscience, aimed at transforming patient lives and Biogen's business through digital tools and solutions.

Companies that use バイオジェン・ジャパン(株)

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

バイオジェン・ジャパン(株) technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

バイオジェン・ジャパン(株) partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Sanofi (サノフィ株式会社)coreGTM or Marketing PartnerSanofi and Biogen Japan jointly utilize healthcare professional personal data for co-hosted seminars, speaker invitations, and disease awareness campaigns targeting healthcare professionals in Japan. Data management responsibility lies with Biogen Japan.
  • Japan Pharma (日本新薬株式会社)coreGTM or Marketing PartnerJapan Pharma collaborates with Biogen Japan on co-promotion activities and healthcare professional engagement related to disease awareness and product information in Japan.
  • Eisai (エーザイ株式会社)coreGTM or Marketing PartnerEisai and Biogen Japan share healthcare professional data for disease awareness, medical product information provision, treatment support, adverse event safety information management, and post-marketing surveillance in Japan.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

バイオジェン・ジャパン(株) competitors and assessment

Company assessment

Direct peers

  • Otsuka Pharmaceutical Co., Ltd. Major Japanese pharma with a CNS/psychiatry franchise (e.g., aripiprazole and related products). Comparable to Biogen Japan in targeting the same neurology/psychiatry specialist channel and in using co-promotion-style commercial models in Japan.
  • Eisai Co., Ltd. Japanese global pharma with a leading neuroscience franchise, most notably lecanemab (Leqembi) for Alzheimer's disease. Direct competitor to Biogen Japan in CNS and Alzheimer's, while simultaneously a co-promotion partner, making it the most directly comparable peer.
  • Sanofi K.K. Global biopharma with multiple sclerosis and rare disease franchises (e.g., teriflunomide/Aubagio). Both a co-promotion partner to Biogen Japan and a direct competitor in MS and rare neurological indications in Japan.
  • Novartis Pharma K.K. (Japan): Operates in Japan's neurology/MS space (e.g., MS therapies) and is a major multinational biopharma with neuroscience exposure. Comparable to Biogen Japan in product category (specialty neurology biologics) and in serving similar specialist HCPs in Japan.
  • Sumitomo Pharma Co., Ltd. Japanese specialty pharma with a strong CNS/psychiatry pipeline (e.g., latuda, regenerative medicine programs). Competes with Biogen Japan in the same specialist neurology and psychiatry prescriber base in Japan.

Broad incumbents

  • Takeda Pharmaceutical Company Limited: Japan's largest pharma with broad neuroscience, rare disease, and plasma-derived therapy franchises. A larger, broadly diversified incumbent with overlapping neurology/rare-disease capability but a much wider portfolio than Biogen Japan.
  • Daiichi Sankyo Co., Ltd. Major Japanese pharma with broad therapeutic areas including neurology adjacencies. While not as CNS-focused as Biogen Japan, it competes for the same specialty-pharma talent, HCP relationships, and co-promotion partners in Japan.
  • Chugai Pharmaceutical Co., Ltd. A Roche-group Japanese biopharma with strong specialty/biologics capabilities (e.g., NMOSD therapy). Comparable in being a Japan-resident biopharma with biologics-heavy product mix and similar regulatory/commercial dynamics.

Emerging players

  • UCB Japan (UCB S.A.): Specialty neurology biopharma with strong presence in epilepsy and rare disease in Japan (e.g., Vimpat, Briviact). Comparable as a specialty/CNS-focused player with concentrated therapeutic-area depth in Japan rather than broad pharma scale.
  • Kyowa Kirin Co., Ltd. Japanese specialty biopharma focused on rare diseases and specialty immunology/neurology (e.g., HLH, rare metabolic). A smaller, focused Japanese peer with rare-disease specialty model comparable to Biogen Japan's SMA franchise approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

バイオジェン・ジャパン(株) social profiles

Digital presence

バイオジェン・ジャパン(株) financial estimates

Financial estimate

Revenue estimate

Valuation estimate

バイオジェン・ジャパン(株) leadership team

Management profile

Number of profiles

Profiles1 record

バイオジェン・ジャパン(株) funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

バイオジェン・ジャパン(株) M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about バイオジェン・ジャパン(株)

What does バイオジェン・ジャパン(株) do?

Biogen Japan develops, registers, and commercializes prescription biopharmaceutical therapies for serious neurological and rare diseases in the Japanese market, with therapeutic focus on Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and spinal muscular atrophy (SMA). The company also operates a Biogen Digital Health division dedicated to individualized digital healthcare solutions in neuroscience. Revenue is generated through product sales to hospitals, clinics, and pharmacies via authorized wholesalers.

Is バイオジェン・ジャパン(株) a public or private company?

バイオジェン・ジャパン(株) is a private company. It is classified as corporate owned and is currently operating.

When was バイオジェン・ジャパン(株) founded?

バイオジェン・ジャパン(株) was founded in -1. It employs 11 to 50 people.

Where is バイオジェン・ジャパン(株) based?

バイオジェン・ジャパン(株) is headquartered in Tokyo, Japan, in the Asia region.

How does バイオジェン・ジャパン(株) make money?

One revenue line is on record: prescription Pharmaceutical Products.

Who are バイオジェン・ジャパン(株)'s main competitors?

Direct peers on record are Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Sanofi K.K., Novartis Pharma K.K. (Japan) and Sumitomo Pharma Co., Ltd.. Broad incumbents are Takeda Pharmaceutical Company Limited, Daiichi Sankyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd.. Emerging players are UCB Japan (UCB S.A.) and Kyowa Kirin Co., Ltd..

Does バイオジェン・ジャパン(株) have an API?

No public API is recorded for バイオジェン・ジャパン(株).

What industry is バイオジェン・ジャパン(株) in?

バイオジェン・ジャパン(株)'s product category is Biopharmaceuticals - Neurology and Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales